Industry News
Pharmaceutical Industry News
For the second time in the last…
For the second time in the last three weeks, AbbVie has revealed successful results from a phase 3 study of Rinvoq as a treatment for alopecia areata.
The financing exercise at Sarepta…
The financing exercise at Sarepta continues as uncertainty remains for the company’s flagship gene therapy Elevidys.
A little less than a month after…
A little less than a month after the reveal of a wide-ranging trade deal between the United States and the European Union, the White House has shed more light on how it plans to tax
Johnson & Johnson will spend…
Johnson & Johnson will spend $2 billion over the next 10 years to operate a 160,000-square-foot manufacturing facility at Fujifilm Diosynth’s massive biomanufacturing campus in Holly Springs, North Carolina, which is scheduled to come online
Nucleus RadioPharma, a CDMO that…
Nucleus RadioPharma, a CDMO that specializes in the burgeoning field of radiopharmaceuticals, named former FDA Commissioner Dr. Stephen Hahn as its chief executive officer.
With topline phase 3 results in…
With topline phase 3 results in sight, Rezolute has stepped up preparations for a planned rare disease launch by appointing Sunil Karnawat as its chief commercial officer.
The FDA has extended its target…
The FDA has extended its target action dates for two applications to expand the use of Eylea’s high-dose formulation. The U.S. regulator was originally scheduled to make its Eylea HD decisions by Aug. 19, but
Unregulated Sexual Stimulants Flood West Africa
Unregulated sexual stimulants claiming to be herbal remedies or pharmaceuticals are flooding the region. Officials are scrambling to address the issue.
A year after earning FDA approval…
A year after earning FDA approval for Kisunla, Eli Lilly is shining a light on the anti-amyloid Alzheimer’s disease therapy in its first branded campaign.
Swoop and iSpot have joined forces…
Swoop and iSpot have joined forces to deliver insights into cross-platform ad exposures against specific audience segments.
Catalent is laying off 350…
Catalent is laying off 350 employees at its gene therapy manufacturing division in Baltimore “due to an unexpected shift in demand from a large customer, which made it necessary to reduce our workforce,” a spokesperson
On a recent earnings call, the…
On a recent earnings call, the Danish drugmaker's newly appointed CEO signaled that he will look over the company's cost base.
A trio of Indian…
A trio of Indian drugmakers—Alembic, Sun and Glenmark—each issued separate voluntary drug recalls due to either the presence of carcinogens or foreign matter in the products.
With three new antibiotics set to…
With three new antibiotics set to shake up the stagnant treatment landscape for uncomplicated urinary tract infections in the U.S., Dublin-based Iterum Therapeutics has made it to market first, edging out generics juggernaut Alembic Pharmaceuticals
Several U.S. pharma companies that…
Several U.S. pharma companies that had posted revenue declines in the first quarter bounced back in the second quarter, including Pfizer, Regeneron and Bristol Myers Squibb. Additionally, Eli Lilly has finally surpassed Novo Nordisk in
The nation’s largest pediatrician…
The nation's largest pediatrician professional organization urged providers and insurers to consider its evidence-backed vaccine recommendations, as opposed to those coming out of a federal advisory panel the health secretary remade to reflect his skepticism
As its lead candidate advances…
As its lead candidate advances into a late-stage trial for pulmonary arterial hypertension, Inhibikase Therapeutics has picked up a commercial leader with plenty of experience in the PAH space.
With sales of atopic dermatitis…
With sales of atopic dermatitis treatment Adbry scaling up in the U.S., Leo Pharma is accomplishing one of the goals established by CEO Christophe Bourdon when he took over at the Danish dermatology specialist in
As it brings a brand beloved in…
As it brings a brand beloved in Mexico stateside, Bayer is stoking nostalgia and a sense of family and tradition to improve its reach among the Hispanic population in the U.S.
Dogged for several years by an…
Dogged for several years by an investor lawsuit accusing the company of misleading investors about the safety and efficacy of its now-approved drug Tavneos, ChemoCentryx has emerged victorious in a securities fraud complaint.